Quintiles Takes Action to Speed Development of Cancer Therapies
News Jan 15, 2009
Quintiles Transnational Corp. announced that it has adopted “common contract language” and will be using the standardized contract clauses developed by the CEO Roundtable on Cancer, a nonprofit group of cancer-fighting CEOs, of which Quintiles is a member.
The adoption of the common contract language has the potential to significantly reduce contract negotiation time, which currently takes a median of 172 days (nearly 6 months) and as much as a year.
“Data clearly demonstrate that the time it takes to get to a final clinical trial agreement is rate-limiting and often the cause of significant delays in the development of experimental drugs,” said Oren Cohen, M.D., Quintiles’ Chief Medical and Scientific Officer and member of the CEO Roundtable Life Sciences Consortium (LSC). “We are hopeful that streamlining the process to begin a cancer trial will shorten the time it takes to get critically-needed therapies to the patients who need them.”
Quintiles, the only contract research organization (CRO) represented, was a significant contributor to the 14-month project which was led by the CEO Roundtable on Cancer’s LSC, a task force of CEO Roundtable members in the oncology pharmaceutical/biotechnology industries in conjunction with the National Cancer Institute.
The group hopes to shorten the drug testing process by making available “common language” for clinical trial contracts through a set of standardized contract clauses for use by NCI-designated cancer centers and the pharmaceutical industry. Click here for more information on the complete report and related documents.
The work included 17 legal and/or business representatives from CEO Roundtable on Cancer LSC companies and 26 representatives from NCI-designated Cancer Centers. This collaborative effort was prompted in part by research demonstrating that the clinical trial contract negotiation phase included numerous opportunities to save precious time.
LSC, led by Dr. Gregory A. Curt, worked to craft “common language” for clinical trial contracts, noting that in the best case, the median time to open a cancer trial is 172 days.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018